Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/11552
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12969]
Metadata
Show full item record
THE EMERGING ROLE OF COMPLEMENT LECTIN PATHWAY IN TRYPANOSOMATIDS: MOLECULAR BASES IN ACTIVATION, GENETIC DEFICIENCIES, SUSCEPTIBILITY TO INFECTION, AND COMPLEMENT SYSTEM-BASED THERAPEUTICS
Complement Lectin Pathway (CLP)
System-Based Therapeutics
Protozoan Parasites
Infectious diseases
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Molecular de Parasitas e Vetores. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Paraná. Departamento de Patologia Medicina. Laboratório de Imunopatologia. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratòrio de Biologia Molecular de Parasitas e Vetores. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Paraná. Departamento de Patologia Medicina. Laboratório de Imunopatologia. Curitiba, PR, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratòrio de Biologia Molecular de Parasitas e Vetores. Rio de Janeiro, RJ, Brasil.
Abstract
The innate immune systemis evolutionary and ancient and is the pivotal line of the host defense systemto protect against invading
pathogens and abnormal self-derived components. Cellular and molecular components are involved in recognition and effector
mechanisms for a successful innate immune response. The complement lectin pathway (CLP) was discovered in 1990. These
new components at the complement world are very efficient. Mannan-binding lectin (MBL) and ficolin not only recognize many
molecular patterns of pathogens rapidly to activate complement but also display several strategies to evade innate immunity.Many
studies have shown a relation between the deficit of complement factors and susceptibility to infection. The recently discovered
CLP was shown to be important in host defense against protozoan microbes. Although the recognition of pathogen-associated
molecular patterns by MBL and Ficolins reveal efficient complement activations, an increase in deficiency of complement factors
and diversity of parasite strategies of immune evasion demonstrate the unsuccessful effort to control the infection. In the present
paper, we will discuss basic aspects of complement activation, the structure of the lectin pathway components, genetic deficiency
of complement factors, and new therapeutic opportunities to target the complement system to control infection.
Keywords
TrypanosomatidsComplement Lectin Pathway (CLP)
System-Based Therapeutics
Protozoan Parasites
Infectious diseases
Share